» Articles » PMID: 15906273

The Origin of Vimentin Expression in Invasive Breast Cancer: Epithelial-mesenchymal Transition, Myoepithelial Histogenesis or Histogenesis from Progenitor Cells with Bilinear Differentiation Potential?

Overview
Journal J Pathol
Specialty Pathology
Date 2005 May 21
PMID 15906273
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Vimentin expression is a rather rare finding in invasive breast cancer, and is associated with high tumour invasiveness and chemoresistance. It is currently explained by two different biological theories: direct histogenetic derivation from myoepithelial cells, and epithelial-mesenchymal transition (EMT) reflecting the end-stage of breast cancer dedifferentiation. In this study we aimed to obtain further insights into the biological hallmarks of these vimentin-expressing breast cancers. We applied immunohistochemistry for vimentin and 15 other differentiation markers to a series of 364 invasive breast cancer cases, using tissue microarray technology. 7.7% of all tumours expressed vimentin. Almost all of these cases (19/21) were Grade 3 invasive ductal carcinomas, and the majority (13/21) of these were associated with a ductal in situ component. Vimentin expression was also seen in the respective in situ components and correlated positively with the expression of SMA, CD10, CK 5, p53, Mib-1 and EGFR. A negative correlation was seen for the expression of CK 8/18 and the oestrogen receptor. Vimentin-expressing carcinomas revealed a significantly higher average absolute number of cytogenetic alterations per case, but a significantly lower frequency of chromosome 16q losses compared to vimentin-negative cases. Our present results demonstrate that, despite analogies between vimentin-positive breast cancers and myoepithelial cells in their expression of differentiation-related proteins, neither myoepithelial histogenesis nor EMT can exclusively explain the biology of these distinct tumours. This is mainly supported by the significantly higher incidence of vimentin-expressing breast cancers compared to any other myoepithelial breast tumours and the fact that vimentin is already observed in ductal in situ components. We therefore propose the alternative hypothesis that vimentin-expressing breast carcinomas may derive from breast progenitor cells with bilinear (glandular and myoepithelial) differentiation potential.

Citing Articles

Structural Characterization of Heat Shock Protein 90β and Molecular Interactions with Geldanamycin and Ritonavir: A Computational Study.

Lima C, Antunes D, Caffarena E, Carels N Int J Mol Sci. 2024; 25(16).

PMID: 39201468 PMC: 11354266. DOI: 10.3390/ijms25168782.


Recurrent mucinous carcinoma with sarcomatoid and sarcomatous mural nodules: a case report and literature review.

Li S, Zhu J, Jiang N, Guo Y, Hou M, Liu X Front Oncol. 2024; 14:1387700.

PMID: 38903727 PMC: 11187075. DOI: 10.3389/fonc.2024.1387700.


A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.

Tzenaki N, Xenou L, Goulielmaki E, Tsapara A, Voudouri I, Antoniou A Commun Biol. 2024; 7(1):26.

PMID: 38182748 PMC: 10770346. DOI: 10.1038/s42003-023-05639-8.


Vimentin: from a cytoskeletal protein to a critical modulator of immune response and a target for infection.

Arrindell J, Desnues B Front Immunol. 2023; 14:1224352.

PMID: 37475865 PMC: 10354447. DOI: 10.3389/fimmu.2023.1224352.


Cell Surface Vimentin Detection in Cancer Cells by Peptide-Based Monoclonal Antibody.

Sadeghi N, Fazli G, Bayat A, Fatemi R, Ebrahimnejhad N, Salimi A Avicenna J Med Biotechnol. 2023; 15(2):68-75.

PMID: 37034891 PMC: 10073919.